Akebia Q2 2024 net loss narrows to $8.6M; Vafseo launch on track for Jan 2025

Akebia Therapeutics, Inc.

2024-Q2 EPS reported -$0.13 revenue$76,255,000

Total revenues $43.6M (down 23% YoY); Auryxia net product rev $41.2M vs $42.2M in Q2 2023.
Net loss $8.6M vs $11.2M in Q2 2023; cash and equivalents $39.5M as of June 30, 2024.
Vafseo TDAPA application submitted; HCPCS codes expected Oct 2024, TDAPA by Jan 2025.
Set Vafseo WAC at $1,278 for 30-day supply (~$15,500/year); regained full U.S. rights from CSL Vifor.
Auryxia FY 2024 net product revenues expected in line with 2023 level ($167M in 2023).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.